Top

Published in:

01-11-2010

Tissue-type plasminogen activator gene targets thrombolysis in atriums

Authors: Yongsheng Gong, Fajiu Wang, Xia Li, Zhixin Gao, Kailun Zhang, Chen Fan, Xingen Liu

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2010

Abstract

Our previous investigations showed that retroviral gene transfer of tissue-type plasminogen activator (tPA) effectively targeted thrombolysis in vitro and in the model of inferior caval veins of rabbits. This study is to identify the target thrombolysis of retroviral vector recombinant pLEGFP-N1-tPA transferred into the tissue around the Dacron patch (the same materials making of the ring of mechanical valve) in left atriums of rabbits. 70 Dacron patches were transplanted into the left atriums of 70 New Zealand white rabbits. The rabbits were randomly divided into three groups according to the different handling methods, including local pLEGFP-N1-tPA transferred group (gene therapy group, 30 animals), pLEGFP-N1 transferred group (control group, 20 animals), medium DMEM + 10% neonate calf serum (NCS) injected group (blank control group, 20 animals). Samples of blood, Dacron pieces and left atriums (auricles) wall from half of above in each group were harvested on second day and another half were harvested on 75th day after surgery. The EGFP expression of harvested left atriums (auricles) wall were observed under the confocal. The thrombi on the surface of Dacron patches were detected by stereoscope and electron microscope. The tPA expression in left atriums (auricles) wall and in blood from left atriums were detected by Western blot and their thrombolysis and activities were observed and calculated in plasma plates. ELISA were used to identify the contents of tPA. No thrombus was seen on the surface of Dacron patches that were transplanted in left atriums by tPA locally transferring around them. Activity and content of tPA were high in local tissue of left atrium and in blood of left atrium. It demonstrated effectively thrombolysis by tPA rapidly, efficiently and long expressing. This puts the foundation of mechanical valve replacement model for tPA gene valve, next.

Sezai A, Hata M, Niino T, Yoda M, Wakui S, Umeda T et al (2007) Prophylactic reoperation after mitral valve replacement with the Starr-Edwards ball valve: a report of four cases. Ann Thorac Cardiovasc Surg 13(5):316–321PubMed

Hopkins RA, St Louis J, Corcoran PC (1991) Ross’ first homograft replacement of the aortic valve. Ann Thorc Surg 52(5):1190–1193CrossRef

Turk R, Varadarajan P, Kamath A, Sampat U, Khandhar S, Patel R et al (2010) Survival benefit of aortic valve replacement in older patients with asymptomatic chronic severe aortic regurgitation. Ann Thorac Surg 89(3):731–737CrossRefPubMed

Agarwala S, Kumar S, Berridge J, Mclenachan J, O’Regan DJ (2006) Double valve replacement for acute spontaneous left chordal rupture secondary to chronic aortic incompetence. J Cardiothorac Surg 1:33CrossRefPubMed

Mckellar SH, Sundt TM (2009) Valve replacement options in the setting of an ascending aortic aneurysm. Future Cardiol 5(4):375–383CrossRefPubMed

Florath I, Albert A, Rosendahl U, Alexander T, Ennker IC, Ennker J (2005) Mid term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves. Heart 91:1023–1029CrossRefPubMed

Allou N, Piednoir P, Berroëta C, Provenchère S, Ibrahim H, Baron G et al (2009) Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin. Heart 95(20):1694–1700CrossRefPubMed

Panda BR, Shankar R, Kuruvilla KT, Philip MA, Thankachen R, Shukla V et al (2009) Combined mitral and aortic valve replacement for rheumatic heart disease: fifteen-year follow up and long-term results. J Heart Valve Dis 18(2):170–179PubMed

Stassano P, Di Tommaso L, Monaco M, Iorio F, Pepino P, Spampinato N et al (2009) Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol 54(20):1862–1868CrossRefPubMed

10.

Accola KD, Scott ML, Spector SD, Thompson PA, Palmer GJ, Sand ME et al (2006) Is the St. Jude Medical mechanical valve an appropriate choice for elderly patients?: a long-term retrospective study measuring quality of life. J Heart Valve Dis 15(1):57–66PubMed

11.

Mol A, Smits AI, Bouten CV, Baaijens FP (2009) Tissue engineering of heart valves: advances and current challenges. Expert Rev Med Devices 6(3):259–275CrossRefPubMed

12.

Vchiyama S (2006) New modalities for the treatment of acute cardioembolic stroke. Inter Med 45:493–494CrossRef

13.

Matsuo O (1981) Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291:590–591CrossRefPubMed

14.

Alexandrov AV (2010) Current and future recanalization strategies for acute ischemic stroke. J Interm Med 267(2):209–219CrossRef

15.

De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS et al (2010) The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke 41(2):295–299CrossRefPubMed

16.

de las Heras N, Cediel E, Oubiña MP, Aragoncillo P, Sanz-Rosa D, Lahera V et al (2003) Comparison between the effects of mixed dyslipidaemia and hypercholestero-laemia on endothelial function, atherosclerotic lesions and fibriolysis in rabbits. Clin Sci 104:357–365CrossRef

17.

Myöhänen H, Vaheri A (2004) Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 61(22):2840–2858CrossRefPubMed

18.

Lindahl TL, Ohlsson PI, Wiman B (1990) The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 265:109–113PubMed

19.

Gong YS, Zhang KL, Jiang XG, Wang ZW, Sun ZQ, Cai J (2007) Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo. Gene Ther 14(21):1537–1542CrossRefPubMed

20.

Longstaff C, Williams S, Thelwell C (2008) Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 6(3):212–213CrossRefPubMed

21.

Ny T, Elgh F, Lund B (1984) The structure of the human tissue-type plasminogen activator gene: correlation of intro and exon structures to functional and structural domains. Proc Natl Acad Sci USA 81(17):5355–5359CrossRefPubMed

22.

Suzuki Y, Mogami H, Ihara H, Urano T (2009) Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 113(2):470–478CrossRefPubMed

23.

van den Eijnde-Schrauwen Y, Atsma DE, Lupu F, de Vries RE, Kooistra T, Emeis JJ (1997) Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. Arterioscler Thromb Vasc Biol 17:2177–2187

24.

Knop M, Gerke V (2002) Ca²⁺-regulated secretion of tissue-type plasminogen activator and von Willebrand factor in human endothelial cells. Biochim Biophys Act 1600:162–167

25.

Dopf J, Horiagon TM (1996) Deletion mapping of the Aequorea Victoria green fluorescent protein. Gene 173:39–44CrossRefPubMed

26.

Bierhuizen MF, Westerman Y, Visser TP, Dimjati W, Wognum AW, Wagemaker G (1997) Enhanced green fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells. Blood 90:3304–3315PubMed

27.

Trinh AT, Ball BG, Weber E, Gallaher TK, Gluzman-Poltorak Z, Anderson F, et al. (2009) Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression. Genet Vaccines Ther. 7:13

28.

Whitcomb JM, Hughes Sh (1992) Retroviral reverse transcription and integration: progress and problems. Ana Rev Cell Biol 8:275–306

29.

Hori S, Nomuta T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Fox P3. Science 299:1057–1061CrossRefPubMed

30.

Chen Y, Ott CJ, Townsend K, Subbaiah P, Aiyar A, Miller WM (2009) Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the Vesicular Stomatitis Virus Glycoprotein (VSV-G). Biochem Eng J 44(2–3):199–207CrossRefPubMed

31.

Varmus HE (1988) Retroviruses. Sciences 240:1427–1435CrossRef

32.

López-Candales Edelman KL (2004) Large atrial appendage thrombus in the presence of severe mitral regurgitation: contradictory hemodynamics or expecte fingings. Echocardiography 21(7):625–629CrossRefPubMed

33.

Miller AD, Miller DG, Garcia JV, Lynch CM (1993) Use of retroviral vector for gene transfer and expression. Methods Enzymol 217:581–599CrossRefPubMed

34.

Cashion LM, Bare LA, Harvey S, Trinh Q, Zhu Y, Devlin JJ (1999) Use of enhanced green fluorescent protein to optimize and quantitate infection of target cells with recombinant retroviruses. Biotechniques 26:924–930PubMed

35.

Edward N (1972) Methods for improving the sensitivity and specifity of the fibrin plate. J Clin Patch 25:335–337CrossRef

36.

Zivin JA (2009) Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Aaministration (FDA). Ann Neurol 66(1):6–10CrossRefPubMed

37.

Seltzem SM, Reed MD, Siwik ES (2006) Intra-atrial tissue plasminogen activator infusion for prosthetic valve thrombosis. Catheter Cardiovasc Intev 67:139–141CrossRef

38.

Torno MD, Kaminski MD, Xie Y, Meyers RE, Mertz CJ, Liu X et al (2008) Improvement of in vitro thrombolysis employing manetically-guided mivrospheres. Throbm Res 121(6):799–811CrossRef

39.

Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA et al (1994) Current protocols in molecular biology. Greene Publishing Associations Inc. and John Wiley & Sons Inc, USA

40.

Reeves L, Smucker P, Cornetta K (2000) Packaging cell line characteristics and optimizing retroviral titer: the additional gene vector laboratory experience. Hum Gene Ther 11:2093–2103CrossRefPubMed

41.

Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D et al (2010) Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115(4):783–791CrossRefPubMed

Title: Tissue-type plasminogen activator gene targets thrombolysis in atriums
Authors: Yongsheng Gong
Fajiu Wang
Xia Li
Zhixin Gao
Kailun Zhang
Chen Fan
Xingen Liu
Publication date: 01-11-2010
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 4/2010
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-010-0523-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tissue-type plasminogen activator gene targets thrombolysis in atriums

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis

Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy

The world through a lens: a history of the Royal Society of London, and the discovery of the red blood cell

Matrix metalloproteinase: investigation from gene to protein as effective factor in myocardial infarction

Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay

Probable endothelisation of bare metal stent struts extending from the left main coronary into the aorta

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page